On July 30, 2025, Viridian Therapeutics announced a collaboration with Kissei Pharmaceutical, granting Kissei exclusive rights to develop and commercialize certain therapeutic products, receiving an upfront payment of $70 million and potential additional payments of up to $315 million based on milestones.